In the offering, the Hayward, Calif.-based company issued approximately 3.6 million shares of common stock at approximately $12.57 per share for total gross proceeds of $45 million.
Pulse Bioscience board chair Robert Duggan, who owns 35% of the company’s outstanding common stock prior to the offering, also participated in the round, purchasing approximately 3.1 million shares for an additional investment of approximately $39.5 million.
After the purchase, Duggan now owns approximately 44% of the company’s outstanding shares, Pulse Biosciences said in a press release.
Shares in Pulse Biosciences are trading 3.6% today, at $11.51 as of 1:06 p.m. EDT.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.